On May 3, 2022 Xilis, Inc., a pioneering company developing its MicroOrganoSphere (MOS) technology to guide precision therapy for cancer patients and accelerate drug discovery and development, reported that it is participating in the recently announced public-private Oncode-PACT (Press release, Xilis, MAY 3, 2022, View Source [SID1234613429]). Led by the Netherlands-based Oncode Institute, the consortium will be supported by the National Growth Fund, an initiative of the Dutch Ministry of Economic Affairs and Climate Policy and the Ministry of Finance.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"Across all cancers there remains tremendous unmet needs for new targeted treatment approaches that address the unique attributes of each patient," said Xiling Shen, PhD, Founder and Chief Executive Officer of Xilis. "Our MOS technology supports the development of new insights into tumor microenvironments and heterogeneity of the originating tumor tissue for accurate, rapid and high-throughput therapeutic profiling. Xilis is proud to be part of Oncode-PACT to help support drug discovery and development and help clinicians make more informed treatment decisions through our European-based office in Netherlands."
Xilis’ proprietary tumorsphere microencapsulation platform evaluates cancer therapies at scale and is designed to enable physicians to make precision oncology treatment decisions, identifying treatments that will led to the best response for each patient.
Alain Kummer, Managing Director Oncode Institute and Chairman of Oncode-PACT, explains: "Oncode-PACT places the patient at the center of the entire drug development chain. In the current situation, the preclinical development process is still insufficiently connected with the clinical practice, and we focus on the patient too late in the drug development process."
Oncode-PACT has the ambition to develop new demonstrably effective cancer drugs faster and more cost-effectively. The medical need is urgent, because cancer remains a leading cause of death worldwide.